• RSS
  • Facebook
  • Twitter
Good People Working on Good Projects with Good Process

Publications

Publications related to Frestedt Incorporated:

FDA Warning Letters About Food Products
How to Avoid or Respond to Citations

Full length book by Dr. Joy Frestedt (with link to buy book)

Warning Letters – 2016 Reference Guidewarningletters

Full length book by Dr. Joy Frestedt (with link to buy book)

GRAS from the ground up: Review of the Interim Pilot Program for GRAS notification

Paul R. Hanlon, PhD, DABT , Joy Frestedt, PhD, CPI, RAC, FRAPS , Kelly Magurany, MSc, DABT

The Investigator’s Brochure: A Real Aid for Drug, Device, and Food Product Trials (Clinical Researcher – October 2014)

Matthew J. Harris, BA; Joy L. Frestedt, PhD, CCTI, RAC, FRAPS

Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001).

Frestedt JL, Young LR, Bell M.

Starting a Clinical Research Program: Is it a natural evolution to your practice?

Wolfe PJ, Frestedt JL.

Reduced viscosity Barley β-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitus.

Bays H, Frestedt JL, Bell M, Williams C, Kolberg L, Schmelzer W, Anderson JW.

A novel liquid multi-phytonutrient supplement demonstrates DNA-protective effects.

Baechler BJ, Nita F, Jones L, Frestedt JL.

A natural seaweed derived mineral supplement (Aquamin F) for knee osteoarthritis: a randomised, placebo controlled pilot study.

Frestedt JL, Kuskowski MA, Zenk JL.

The Role and Impact of the Principal Investigator

Joy Frestedt, PhD, RAC, CCTI

A whey-protein supplement increases fat loss and spares lean muscle in obese subjects: a randomized human clinical study.

Frestedt JL, Zenk JL, Kuskowski MA, Ward LS, Bastian ED.

In November 2017, This Alimentix clinical trial was cited in Medical News Today in the news article, What are the benefits and risks of whey protein?

A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial.

Frestedt JL, Walsh M, Kuskowski MA, Zenk JL.

HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults.

Zenk JL, Frestedt JL, Kuskowski MA.

AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments.

Li Q, Frestedt JL, Kersey JH.

MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia.

Hilden JM, Smith FO, Frestedt JL, McGlennen R, Howells WB, Sorensen PH, Arthur DC, Woods WG, Buckley J, Bernstein ID, Kersey JH.

Molecular analysis of infant acute leukemia.

Hilden JM, Frestedt JL, Kersey JH.

AF4/FEL, a gene involved in infant leukemia: sequence variations, gene structure, and possible homology with a genomic sequence on 5q31.

Frestedt JL, Hilden JM, Kersey JH.

Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age.

Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH.

Differential expression of AF4/FEL mRNA in human tissues.

Frestedt JL, Hilden JM, Moore RO, Kersey JH.

Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).

Hilden JM, Frestedt JL, Moore RO, Heerema NA, Arthur DC, Reaman GH, Kersey JH.

Acute lymphoblastic leukemias with deletion of 11q23 or a novel inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features.

Raimondi SC, Frestedt JL, Pui CH, Downing JR, Head DR, Kersey JH, Behm FG.

Heterogeneity in MLL/AF-4 fusion messenger RNA detected by the polymerase chain reaction in t(4;11) acute leukemia.

Hilden JM, Chen CS, Moore R, Frestedt J, Kersey JH.

The chromosome 4q21 gene (AF-4/FEL) is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia.

Chen CS, Hilden JM, Frestedt J, Domer PH, Moore R, Korsmeyer SJ, Kersey JH.

Cell-surface expression of immunoglobulin G receptors on the polymorphonuclear leukocytes and monocytes of extremely premature infants.

Payne NR, Frestedt J, Hunkeler N, Gehrz R.

Recurring chromosome abnormalities in Hodgkin’s disease.

Döhner H, Bloomfield CD, Frizzera G, Frestedt J, Arthur DC.

Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia.

Machnicki JL, Bloomfield CD.

Clinical significance of the cytogenetics of acute leukemias.

Machnicki JL, Bloomfield CD.

Sequential karyotypes in non-Hodgkin lymphoma: their nature and significance.

Levine EG, Juneja S, Arthur D, Garson OM, Machnicki JL, Frizzera G, Ironside P, Cooper I, Hurd DD, Peterson BA, et al.

Four new recurring translocations in non-Hodgkin lymphoma.

Levine EG, Arthur DC, Machnicki J, Frizzera G, Hurd D, Peterson B, Gajl-Peczalska KJ, Bloomfield CD.

Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

Keinänen M, Bloomfield CD, Machnicki J, Griffin JD, de la Chapelle A.

Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia.

Keinänen M, Griffin JD, Bloomfield CD, Machnicki J, de la Chapelle A.

In vitro correlates of low dose ara-C efficacy: clinical, cytogenetic, and bone marrow culture analysis.

Weisdorf DJ, Perri RT, Arthur DC, Machnicki JL, Oken MM, Miller WJ.

Thriving through the experience: An Assessment Guide for Graduate and Professional Students

Frestedt J, Crone W, James K, Morgan J.

.